Compositions and methods of treating inflammatory bowel disease
A method of treating a lymphocyte mediated inflammation in a subject including administering a therapeutically effective amount of a cell delivery composition to the subject, the cell delivery composition of the application including an immunosuppressive cell and a plurality of targeting moieties that bind to endothelial cell adhesion molecules expressed by endothelial cells as a result of a lymphocyte mediated inflammatory response in the subject, the targeting moieties coated on and linked to the immunosuppressive cell and enhancing adherence of the immunosuppressive cell to an endothelial cell at a site of lymphocyte mediated inflammation when administered to the subject systemically, wherein the cell delivery composition, suppresses lymphocyte mediated inflammation in the subject.
1. A method of treating inflammatory bowel disease in a subject, the method comprising:
administering a therapeutically effective amount of a cell delivery composition to the subject, the cell delivery composition comprising an mesenchymal stem cell and a plurality of targeting moieties that bind to endothelial cell adhesion molecules expressed by endothelial cells in the colon and small intestine of the subject, the targeting moieties being coated on and linked to the mesenchymal stem cell and enhancing adherence of the mesenchymal stem cell to an endothelial colon and small intestine cell of the subject when administered to the subject systemically, wherein the cell delivery composition suppresses inflammation in the colon and small intestine of the subject.
2. The method of claim 1 , the endothelial cell adhesion molecule comprising an immunoglobulin superfamily cell adhesion molecule selected from the group consisting of ICAM1, ICAM2, ICAM3, VCAM1, and MAdCAM.
3. The method of 1 , wherein the plurality of targeting moieties comprises an antibody or fragment thereof that binds to an endothelial cell adhesion molecule.
4. The method of claim 1 , wherein the cell delivery composition is administered to the subject by intravenous injection.
5. The method of 1 , wherein the endothelial cell is an activated endothelial cell.
6. The method of claim 1 , wherein the mesenchymal stem cell is pre-coated with a linker.
7. The method of claim 6 , wherein the linker is selected from protein G and protein A.
8. The method of claim 1 , wherein the mesenchymal stem cell is directly linked to the plurality of targeting moieties.
9. The method of claim 8 , wherein the plurality of targeting moieties are modified with a lipophilic moiety.
10. The method of claim 1 , wherein the mesenchymal stem cell is an allogeneic mesenchymal stem cell.
11. The method of claim 1 , wherein the mesenchymal stem cell is an autologous mesenchymal stem cell.
12. The method of claim 1 , the endothelial cell adhesion molecule comprising MAdCAM.